CAR T-Cell Therapy for Leukemia

"That is correct. The information on clinicaltrials.gov does show that this particular trial is looking for participants at the moment. This trial was first posted on 9/20/2022 and was last updated on 10/5/2022. They are searching for a total of 89 patients from 1 site."

"Presently, this clinical trial is seeking enrolment from patients. All information regarding the study was first posted on September 20th, 2022 with the most recent edit taking place on October 5th, 2022."

"The age range for participants in this clinical trial is 0 to 29 years old. Out of all the 477 similar studies, this one focuses on a younger patient demographic. There are 1229 trials for patients over 65 years old."

"The primary outcome of this study is the safety of huCART19 administration, which will be assessed over a period of approximately 5 years. Secondary outcomes include remission rate (defined as the overall remission rate among treated subjects at Day 28 post-huCART19 infusion), manufacturing feasibility (defined as the percentage of manufactured products that meet release criteria for vector transduction efficiency, T cell product purity, viability, and sterility), and event-free survival (defined as 1-year Event-Free Survival in subjects with relapsed/refractory B-ALL [Cohort A] and in subjects with poor response to"

"This study is seeking to enroll 89 young patients, aged 0-29, who have b-lymphocytes and meet the following additional inclusion criteria: Signed informed consent, relapsed or refractory ALL or Lly, poor response to prior B cell directed engineered cell therapy, CNS3 disease responsive to therapy , CD19 tumor expression in bone marrow, peripheral blood, cerebrospinal fluid (CSF), or tumor tissue by flow cytometry , age 0-29 years old , adequate organ function , adequate performance status defined as Lansky or Karnofsky performance score ≥50. Subjects of reproductive potential must agree to use acceptable birth"